Nothing Special   »   [go: up one dir, main page]

AU4187200A - The use of domains of type iv collagen t inhibit angiogenesis an tumour growth - Google Patents

The use of domains of type iv collagen t inhibit angiogenesis an tumour growth

Info

Publication number
AU4187200A
AU4187200A AU41872/00A AU4187200A AU4187200A AU 4187200 A AU4187200 A AU 4187200A AU 41872/00 A AU41872/00 A AU 41872/00A AU 4187200 A AU4187200 A AU 4187200A AU 4187200 A AU4187200 A AU 4187200A
Authority
AU
Australia
Prior art keywords
collagen
domains
type
tumour growth
inhibit angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU41872/00A
Inventor
Peter Brooks
Billy Hudson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biostratum Inc
Original Assignee
Biostratum Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biostratum Inc filed Critical Biostratum Inc
Publication of AU4187200A publication Critical patent/AU4187200A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU41872/00A 1999-04-01 2000-03-31 The use of domains of type iv collagen t inhibit angiogenesis an tumour growth Abandoned AU4187200A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12739199P 1999-04-01 1999-04-01
US60127391 1999-04-01
PCT/US2000/008678 WO2000059532A1 (en) 1999-04-01 2000-03-31 The use of domains of type iv collagen t inhibit angiogenesis an tumour growth

Publications (1)

Publication Number Publication Date
AU4187200A true AU4187200A (en) 2000-10-23

Family

ID=22429859

Family Applications (1)

Application Number Title Priority Date Filing Date
AU41872/00A Abandoned AU4187200A (en) 1999-04-01 2000-03-31 The use of domains of type iv collagen t inhibit angiogenesis an tumour growth

Country Status (2)

Country Link
AU (1) AU4187200A (en)
WO (1) WO2000059532A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440729B1 (en) 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
US6358735B1 (en) 1995-06-30 2002-03-19 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
US7387779B2 (en) 1998-06-17 2008-06-17 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US6962974B1 (en) 1998-06-17 2005-11-08 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US6759047B1 (en) 1998-06-17 2004-07-06 Beth Israel Deaconess Hospital Corp. Anti-angiogenic proteins and methods of use thereof
CN1420926A (en) * 2000-01-07 2003-05-28 贝丝以色列迪克尼斯医疗中心 Anti-angiogenic proteins and fragments and methods of use thereof
JP2005504037A (en) 2001-07-27 2005-02-10 ユニヴァースティ オブ カンザス メディカル センター Crystallization structure of type IV collagen NC1 domain hexamer
US7662783B2 (en) 2003-02-20 2010-02-16 New York University CLK-peptide and SLK-peptide
US7601694B2 (en) * 2003-02-20 2009-10-13 New York University CLK-peptide and SLK-peptide
US7387998B2 (en) 2003-03-28 2008-06-17 New York University STQ peptides
WO2007087689A1 (en) * 2006-02-03 2007-08-09 Crc For Asthma And Airways Ltd A method of modulating cellular activity and agents for use therein

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5567609A (en) * 1994-06-30 1996-10-22 University Of Kansas Medical Center Use of isolated domains of type IV collagen to modify cell and tissue interactions
CA2318432C (en) * 1998-03-27 2003-01-28 University Of Kansas Medical Center The use of isolated domains of type iv collagen to modify cell and tissue interactions

Also Published As

Publication number Publication date
WO2000059532A9 (en) 2001-11-15
WO2000059532A1 (en) 2000-10-12

Similar Documents

Publication Publication Date Title
AU2212600A (en) Antisense modulation of g-alpha-i1 expression
AU6296099A (en) Antisense modulation of g-alpha-12 expression
AU5639900A (en) Shaped scalpel
AU2492000A (en) Implantable neuro-stimulator
AU3791601A (en) Treatment of coal
AU3924300A (en) Fibroblast growth factor-20
AU5562999A (en) Methods of modulating of angiogenesis
AU4187200A (en) The use of domains of type iv collagen t inhibit angiogenesis an tumour growth
AUPQ137699A0 (en) Control of acidosis
AU2001264769A1 (en) Induction of apoptosis and cell growth inhibition by protein 4.33
AU6115400A (en) Antisense modulation of mekk5 expression
AU7876900A (en) Antisense modulation of fra-1 expression
AU2209000A (en) Antisense modulation of pepck-mitochondrial expression
AU5322900A (en) Modulation of protein levels using the scf complex
AU5486700A (en) Antisense modulation of g-alpha-s1 expression
AU1916601A (en) Oncolytic combinations for the treatment of cancer
AU1916501A (en) Oncolytic combinations for the treatment of cancer
AU3978700A (en) Medical use
AU1921100A (en) Antisense modulation of smad4 expression
AU2410600A (en) Antisense modulation of g-alpha-i3 expression
AU5026600A (en) Methods of regulating the condition of mammalian keratinous tissue
AU5394300A (en) Tissue engineering
AU5124500A (en) Tumor necrosis factor-gamma
AU5914299A (en) Antagonists of fibroblast growth factor
AU1595001A (en) Oncolytic combinations for the treatment of cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase